Eisai said on July 8 that its new drug application for the sleep inducer Dayvigo (lemborexant) has been accepted for review by Hong Kong’s health authorities, making it the first Asian market to do so outside Japan. The submission seeks…
To read the full story
Related Article
- Eisai’s Sleep Inducer Dayvigo Now Available in Hong Kong
July 1, 2021
- Eisai’s Sleep Inducer Dayvigo Approved in Hong Kong
March 3, 2021
BUSINESS
- Sanofi Bets on Immunotherapy to Delay Onset of Type 1 Diabetes
December 19, 2025
- Japan’s 1st Eylea Biosimilar to Reach Market on January 7
December 19, 2025
- Padcev-Keytruda Pair Makes Mark in Cisplatin-Eligible MIBC: Astellas
December 19, 2025
- Daiichi Sets February Launch for Japan’s 1st OTC Morning-After Pill
December 19, 2025
- Takeda’s TYK2 Inhibitor Scores PIII Win in Psoriasis Trials, Tops Otezla on Key Metrics
December 19, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





